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Sir,
We fully agree that early detection of colorectal cancer (CRC)
should not only focus on cancerous lesions but also on clinically
relevant precursors to CRC, bearing the potential to reduce both
incidence and mortality of the disease. Nevertheless, when
evaluating and characterising a screening test, it appears reason-
able to clearly distinguish between sensitivity for CRC and
sensitivity for precursors to CRC, as these test characteristics
imply different clinical priorities. Colorectal cancer already
present has high priority to be detected immediately since further
growth significantly reduces chances of survival. By contrast,
precursors to CRC offer the possibility to be detected by repeated
testing before they become malignant at all (eg, within
annual screening schemes) due to their typically long latency
period. Thus, sensitivities for both lesions should be valued
differently. In our study, it was only possible to estimate sensitivity
of the tumour M2-PK test for CRC (which was precisely referred as
that). Shastri and Stein tried to calculate a summary estimate for
both lesions, which they referred to as sensitivity for colorectal
neoplasia (CRN). Apart from our principal concerns regarding the
meaningfulness of such a summary estimate for reasons men-
tioned above, it is important to do the calculations methodologi-
cally correctly, that is by considering the relative frequencies of
CRC and its precursors in the general population. Shastri and
Stein, however, used the estimated frequencies of CRC and its
precursors in our total study population, which, given the
underlying case–control design, reflects a completely arbitrary
CRC/precursor ratio.
We extensively discussed the issue that controls in our study did
not undergo colonoscopy and provided detailed model calcula-
tions to estimate the resulting error regarding specificity. With a
prevalence of 1% of undiagnosed CRC among controls, specificity
in terms of detecting CRC (ie, healthy means not having CRC)
would have been underestimated by no more than 0.5% units
(73.5% rather than 73.0%).
Given the comparatively low specificity of the tumour M2-PK
test observed in our study, we deliberately discussed with caution
whether its implementation in a population-based screening
setting is justifiable, from both an ethical and an economic point
of view. We miss comparable due caution in the reasoning of
Shastri and Stein regarding immunological faecal occult blood
testing (IFOBT), which appears to have higher specificity, but
lower sensitivity compared with the tumour M2-PK test. The
question which of both tests, if any, would be more appropriate for
screening is very complex (see, for example, Haug and Brenner,
2005) and far from being answered by the selected data cited by
Shastri and Stein. By the way, using results from the largest
screening study that has been done on IFOBT (where sensitivities
for advanced neoplasia and for invasive CRC were 27.1 and 65.8%,
respectively) (Morikawa et al, 2005) would yield an estimate of
sensitivity for CRN far below the level of 48% referred to as highly
unacceptable by Shastri and Stein elsewhere in their letter.
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